Display options
Cite
Xu Y, Pan Y, Zhou Z. Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model. J Thorac Dis. 2019;11(11):4671-4681doi: 10.21037/jtd.2019.10.58.
Xu, Y., Pan, Y., & Zhou, Z. (2019). Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model. Journal of thoracic disease, 11(11), 4671-4681. https://doi.org/10.21037/jtd.2019.10.58
Xu, Yunhua, et al. "Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model." Journal of thoracic disease vol. 11,11 (2019): 4671-4681. doi: https://doi.org/10.21037/jtd.2019.10.58
Xu Y, Pan Y, Zhou Z. Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model. J Thorac Dis. 2019 Nov;11(11):4671-4681. doi: 10.21037/jtd.2019.10.58. PMID: 31903256; PMCID: PMC6940230.
Copy Download .nbib Format: NLM
Share it on

J Thorac Dis. 2019 Nov;11(11):4671-4681. doi: 10.21037/jtd.2019.10.58.

Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model.

Journal of thoracic disease

Yunhua Xu, Yan Pan, Zhen Zhou

Affiliations

  1. Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
  2. Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.

PMID: 31903256 PMCID: PMC6940230 DOI: 10.21037/jtd.2019.10.58

Abstract

BACKGROUND: To investigate the effects of recombinant human thrombopoietin (rhTPO) and interleukin-2 (IL-2) on a basic gemcitabine (GEM) plus carboplatin (GC) treatment regimen in a murine lung carcinoma model.

METHODS: Fifty nude mice with subcutaneous tumors derived from human lung cancer cells were divided into 5 groups, each comprised of 10 mice: A blank group (intraperitoneal injection of saline), a control group (GC) (intraperitoneal injections of GC), a rhTPO group (same as the control group plus subcutaneous injection of rhTPO), an IL-2 group (same as the control group plus subcutaneous injection of IL-2) and a rhTPO + IL-2 group (same as the rhTPO group plus subcutaneous injection of IL-2). Tumor development and histology as well as CD4+, phosphorylated-adenosine monophosphate-activated protein kinase (p-AMPK), phosphorylated-protein kinase B (p-AKT), phosphorylated-extracellular signal-regulated kinase (p-ERK), phosphorylated-phosphoinositide 3-kinase (p-pI3K) and GTPase RAS1 expression in tumor tissues were measured and blood analyses performed.

RESULTS: Tumor sizes from all treated mice were significant smaller than the controls, as were the tumors of IL-2 plus GC treated mice compared to other treated groups. CD4+ expressing cells were increased in tumors after IL-2 and rhTPO treatment and the application of rhTPO significantly restored the blood platelet count. The expression of p-AMPK, p-AKT, p-ERK, p-pI3K and RAS1 in tumor cells were all significantly diminished after the addition of rhTPO and IL-2 to the GC regimen.

CONCLUSIONS: The supplementation of rhTPO and IL-2 to a GC regime effectively reduced tumor sizes and restored the platelet count in a human lung cancer mouse model.

2019 Journal of Thoracic Disease. All rights reserved.

Keywords: Recombinant human thrombopoietin (rhTPO); carboplatin; gemcitabine (GEM); interleukin-2 (IL-2); lung carcinoma; mouse model

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

  1. Am J Clin Oncol. 1995 Feb;18(1):47-51 - PubMed
  2. Biol Blood Marrow Transplant. 2011 Sep;17(9):1308-15 - PubMed
  3. J Chemother. 2011 Feb;23(1):40-3 - PubMed
  4. Eur J Surg Oncol. 1995 Feb;21(1):16-22 - PubMed
  5. Oncoimmunology. 2016 Apr 25;5(6):e1163462 - PubMed
  6. Cancer. 1995 Feb 15;75(4):1030-7 - PubMed
  7. Exp Hematol. 1998 Mar;26(3):207-16 - PubMed
  8. Tumori. 1994 Dec 31;80(6):464-7 - PubMed
  9. Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):395-9 - PubMed
  10. Pharmacology. 2016;98(5-6):284-293 - PubMed
  11. Anticancer Drugs. 1995 Dec;6 Suppl 6:61-2 - PubMed
  12. Tumori. 1998 Jan-Feb;84(1):33-8 - PubMed
  13. J Immunother. 1997 Sep;20(5):354-64 - PubMed
  14. Nat Med. 2005 Nov;11(11):1238-43 - PubMed
  15. J Immunol. 2008 Nov 15;181(10):6942-54 - PubMed
  16. Circulation. 2012 Sep 4;126(10):1256-66 - PubMed
  17. Int J Hematol. 2017 Dec;106(6):765-776 - PubMed
  18. Gynecol Oncol Res Pract. 2017 Nov 14;4:16 - PubMed
  19. Lung Cancer. 1999 Sep;25(3):199-206 - PubMed
  20. Cancer Res. 2015 Sep 1;75(17):3583-95 - PubMed
  21. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Feb;26(1):234-238 - PubMed
  22. Biol Blood Marrow Transplant. 2003 Jun;9(6):405-13 - PubMed
  23. Oral Oncol. 2013 May;49(5):468-74 - PubMed
  24. Cancer. 1994 Mar 1;73(5):1353-60 - PubMed
  25. Sci Transl Med. 2013 Apr 3;5(179):179ra43 - PubMed
  26. Blood Rev. 1989 Jun;3(2):110-9 - PubMed
  27. J Exp Med. 2010 Aug 30;207(9):1871-8 - PubMed
  28. Int J Hematol. 2008 Mar;87(2):217-224 - PubMed
  29. Zhonghua Yi Xue Za Zhi. 2004 Mar 2;84(5):397-400 - PubMed
  30. Medicine (Baltimore). 2017 Dec;96(50):e9302 - PubMed
  31. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Apr;13(2):198-204 - PubMed
  32. N Engl J Med. 2011 Dec 1;365(22):2055-66 - PubMed
  33. Nature. 1981 May 28;291(5813):335-8 - PubMed
  34. Exp Hematol. 1992 Sep;20(8):962-8 - PubMed
  35. Br J Haematol. 2001 Sep;114(3):660-5 - PubMed

Publication Types